Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer 14 May 2024
Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical... Read more